Cargando…

Rapid Decrease of Intact Parathyroid Hormone Could Be a Predictor of Better Response to Cinacalcet in Hemodialysis Patients

PURPOSE: Cinacalcet is effective for treating refractory secondary hyperparathyroidism (SHPT), but little is known about the response rates and clinical factors influencing the response. MATERIALS AND METHODS: A prospective, single-arm, multi-center study was performed for 24 weeks. Cinacalcet was a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jwa-Kyung, Kwon, Young Joo, Kim, Soo Wan, Kim, Yeong-Hoon, Park, Cheol Whee, Choi, Kyu Bok, Hwang, Seung Duk, Choi, Kyu Hun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575968/ https://www.ncbi.nlm.nih.gov/pubmed/23364981 http://dx.doi.org/10.3349/ymj.2013.54.2.453

Ejemplares similares

Intact parathyroid hormone and whole parathyroid hormone assay results disagree in hemodialysis patients under cinacalcet hydrochloride therapy
por: Koda, Ryo, et al.
Publicado: (2014)

The administration of cinacalcet hydrochloride just before a haemodialysis session suppresses the transient rise in intact parathyroid hormone induced by a low-calcium dialysate: when should cinacalcet hydrochloride be administered?
por: Date, Toshiyuki, et al.
Publicado: (2008)

A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent hemodialysis patients
por: Villa-Bellosta, Ricardo, et al.
Publicado: (2017)

The Effect of the Frequently Used Cinacalcet for pHPT during the COVID-19 Pandemic on Perioperative Decrease in Parathyroid Hormone
por: Radulova-Mauersberger, Olga, et al.
Publicado: (2022)

Parathyroid Hormone Concentrations in Maintenance Hemodialysis: Longitudinal Evaluation of Intact and Biointact Assays
por: Berner, Carolin, et al.
Publicado: (2021)

Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients
por: Zheng, Cai-Mei, et al.
Publicado: (2018)

Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism
por: Di Dalmazi, Giulia, et al.
Publicado: (2018)

Rescue of High Glucose Impairment of Cultured Human Osteoblasts Using Cinacalcet and Parathyroid Hormone
por: Shahen, V. A., et al.
Publicado: (2023)

The use of cinacalcet in pregnancy to treat a complex case of parathyroid carcinoma
por: Nadarasa, K, et al.
Publicado: (2014)

Cinacalcet for Hypercalcemia Caused by Pulmonary Squamous Cell Carcinoma Producing Parathyroid Hormone-Related Peptide
por: Bech, Anneke, et al.
Publicado: (2012)

Parathyroid carcinoma survival: improvements in the era of intact parathyroid hormone monitoring?
por: Allen, Miya E., et al.
Publicado: (2013)

The optimal range of serum intact parathyroid hormone for a lower risk of mortality in the incident hemodialysis patients
por: Zhou, Xiaoling, et al.
Publicado: (2021)

Effects of cinacalcet treatment on QT interval in hemodialysis patients
por: Temiz, Gökhan, et al.
Publicado: (2016)

Successful use of cinacalcet to treat parathyroid-related hypercalcemia in two pediatric patients
por: Mogas, E, et al.
Publicado: (2018)

Case report of a cystic parathyroidal adenoma with rapid growth induced by cinacalcet
por: Werner, Christoph, et al.
Publicado: (2020)

SAT-349 Cinacalcet Resistant Tertiary Hyperparathyroidism with One Large Parathyroid Gland
por: Chaker, Bayan, et al.
Publicado: (2020)

Clinical usefulness of intraoperative parathyroid hormone monitoring for primary hyperparathyroidism
por: Paek, Se Hyun, et al.
Publicado: (2018)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Alvarado, Luis, et al.
Publicado: (2022)

Association between vascular access failure and microparticles in hemodialysis patients
por: Ryu, Jung-Hwa, et al.
Publicado: (2012)

Successful cinacalcet treatment of refractory secondary hyperparathyroidism due to multiple lung parathyroid adenomas
por: Sugi, Orie, et al.
Publicado: (2010)

Effect of Citrate-Acidified Dialysate on Intact Parathyroid Hormone in Prevalent Hemodialysis Patients: A Matched Retrospective Cohort Study
por: Ficociello, Linda H, et al.
Publicado: (2021)

Cinacalcet-mediated activation of the CaMKKβ-LKB1-AMPK pathway attenuates diabetic nephropathy in db/db mice by modulation of apoptosis and autophagy
por: Lim, Ji Hee, et al.
Publicado: (2018)

The Relationship between Magnesium and Endothelial Function in End-Stage Renal Disease Patients on Hemodialysis
por: Lee, Shina, et al.
Publicado: (2016)

Comparative Gene Expression Profiles in Parathyroid Adenoma and Normal Parathyroid Tissue
por: Chai, Young Jun, et al.
Publicado: (2019)

Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism
por: Ni, Zhaohui, et al.
Publicado: (2023)

Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD
por: Miller, Gerald, et al.
Publicado: (2012)

Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction
por: Zitt, Emanuel, et al.
Publicado: (2013)

Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study
por: St. Peter, Wendy L, et al.
Publicado: (2015)

Osteopontin Levels in Patients With Chronic Kidney Disease Stage 5 on Hemodialysis Directly Correlate With Intact Parathyroid Hormone and Alkaline Phosphatase
por: Druck, Aleksander, et al.
Publicado: (2019)

Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism
por: Meola, Mario, et al.
Publicado: (2009)

Association Between Resistance to Cinacalcet and Parathyroid Gland Hyperplasia in Kidney Transplant Recipients with Persistent Hypercalcemia
por: Oruc, A., et al.
Publicado: (2020)

Early fluid management affects short-term mortality in patients with end-stage kidney disease undergoing chronic hemodialysis and requiring continuous renal replacement therapy
por: Kim, Kyun Young, et al.
Publicado: (2022)

Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events Trial
Publicado: (2015)

Mechanistic analysis for time-dependent effects of cinacalcet on serum calcium, phosphorus, and parathyroid hormone levels in 5/6 nephrectomized rats
por: Wu-Wong, J Ruth, et al.
Publicado: (2013)

AST-120 Improves Microvascular Endothelial Dysfunction in End-Stage Renal Disease Patients Receiving Hemodialysis
por: Ryu, Jung-Hwa, et al.
Publicado: (2016)

Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
por: Kuczera, Piotr, et al.
Publicado: (2016)

Malignant Hypercalcemia Induced by the Ectopic Production of Intact Parathyroid Hormone (PTH)
por: Neves, Ana, et al.
Publicado: (2023)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case report
por: Takada, Daisuke, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2b6kuie566vlu9bib37ciamqlh